http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 02 Jun 2026 06:57:07 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+Precigen+Inc.+%28PGEN%29/26587096.html <p>H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating and $14.00 price target on Precigen Inc. (NASDAQ: PGEN).</p><p>The analyst commented: "On May 30, 2026, at the 2026 annual meeting of the American Society of Clinical Oncology (ASCO), Precigen presented mature follow-up data from the pivotal trial with PAPZIMEOS (zopapogene imadenovec-drba) that evaluated the drug as a therapy for recurrent respiratory papillomatosis (RRP). As of the April 30, 2026 assessment, 15 of 18 complete responders (83%) remained in complete response and had received no further RRP treatment of any kind during the follow-up period, be it surgery or off-label investigational agents. http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+Precigen+Inc.+%28PGEN%29/26587096.html Tue, 02 Jun 2026 06:57:07 -0400 PGEN http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PRECIGEN%2C+INC.++++++++++++For%3A+May+28++Filed+by%3A+Tennant+Phil/26584153.html si-local-file:///var/storage/secattach/20260601/26584153.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PRECIGEN%2C+INC.++++++++++++For%3A+May+28++Filed+by%3A+Tennant+Phil/26584153.html Mon, 01 Jun 2026 16:29:00 -0400 O.13607936 PGEN http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PRECIGEN%2C+INC.++++++++++++For%3A+May+28++Filed+by%3A+Tennant+Phil/26584153.html si-local-file:///var/storage/secattach/20260601/26584153.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PRECIGEN%2C+INC.++++++++++++For%3A+May+28++Filed+by%3A+Tennant+Phil/26584153.html Mon, 01 Jun 2026 16:29:00 -0400 O.13607936 PGEN http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PRECIGEN%2C+INC.++++++++++++For%3A+May+28++Filed+by%3A+Thomasian+Harry+Jr./26584166.html si-local-file:///var/storage/secattach/20260601/26584166.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PRECIGEN%2C+INC.++++++++++++For%3A+May+28++Filed+by%3A+Thomasian+Harry+Jr./26584166.html Mon, 01 Jun 2026 16:29:00 -0400 O.13607936 PGEN http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PRECIGEN%2C+INC.++++++++++++For%3A+May+28++Filed+by%3A+Thomasian+Harry+Jr./26584166.html si-local-file:///var/storage/secattach/20260601/26584166.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PRECIGEN%2C+INC.++++++++++++For%3A+May+28++Filed+by%3A+Thomasian+Harry+Jr./26584166.html Mon, 01 Jun 2026 16:29:00 -0400 O.13607936 PGEN http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PRECIGEN%2C+INC.++++++++++++For%3A+May+28++Filed+by%3A+Lehr+Donald+P./26584120.html si-local-file:///var/storage/secattach/20260601/26584120.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PRECIGEN%2C+INC.++++++++++++For%3A+May+28++Filed+by%3A+Lehr+Donald+P./26584120.html Mon, 01 Jun 2026 16:27:00 -0400 O.13607936 PGEN http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PRECIGEN%2C+INC.++++++++++++For%3A+May+28++Filed+by%3A+Lehr+Donald+P./26584120.html si-local-file:///var/storage/secattach/20260601/26584120.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PRECIGEN%2C+INC.++++++++++++For%3A+May+28++Filed+by%3A+Lehr+Donald+P./26584120.html Mon, 01 Jun 2026 16:27:00 -0400 O.13607936 PGEN http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PRECIGEN%2C+INC.++++++++++++For%3A+May+28++Filed+by%3A+Shah+Rutul+R/26584130.html si-local-file:///var/storage/secattach/20260601/26584130.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PRECIGEN%2C+INC.++++++++++++For%3A+May+28++Filed+by%3A+Shah+Rutul+R/26584130.html Mon, 01 Jun 2026 16:27:00 -0400 O.13607936 PGEN http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PRECIGEN%2C+INC.++++++++++++For%3A+May+28++Filed+by%3A+Shah+Rutul+R/26584130.html si-local-file:///var/storage/secattach/20260601/26584130.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PRECIGEN%2C+INC.++++++++++++For%3A+May+28++Filed+by%3A+Shah+Rutul+R/26584130.html Mon, 01 Jun 2026 16:27:00 -0400 O.13607936 PGEN http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PRECIGEN%2C+INC.++++++++++++For%3A+May+28++Filed+by%3A+Sabzevari+Helen/26584099.html si-local-file:///var/storage/secattach/20260601/26584099.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PRECIGEN%2C+INC.++++++++++++For%3A+May+28++Filed+by%3A+Sabzevari+Helen/26584099.html Mon, 01 Jun 2026 16:26:00 -0400 O.13607936 PGEN http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PRECIGEN%2C+INC.++++++++++++For%3A+May+28++Filed+by%3A+Sabzevari+Helen/26584099.html si-local-file:///var/storage/secattach/20260601/26584099.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PRECIGEN%2C+INC.++++++++++++For%3A+May+28++Filed+by%3A+Sabzevari+Helen/26584099.html Mon, 01 Jun 2026 16:26:00 -0400 O.13607936 PGEN http://www.streetinsider.com/Press+Releases/Precigen+Presents+New+Long-Term+Durability+Data+for+PAPZIMEOS%2C+Recently+Granted+Seven-Year+Market+Exclusivity%2C+Demonstrating+Complete+Responses+Beyond+4+Years/26577264.html <div class="xn-content"> <ul type="disc"><li><i><span>15 out of 18 complete responders, or 83%, demonstrated ongoing complete responses for at least 36 months without any additional treatment for RRP</span></i></li><li><i><span>5 complete responders have ongoing responses beyond 4 years</span></i></li><li><i><span>Follow-up is ongoing; median duration of complete response has not yet been reached</span></i></li><li><i><span>No new adverse safety events have been observed during long-term follow-up</span></i></li><li><i><span><span value="ACORN:0682203466" idsrc="xmltag.org" >US FDA</span> granted seven-year period of orphan drug market exclusivity to PAPZIMEOS</span></i></li></ul><p><span class="legendSpanClass"><location value="LU/us.md.gerown" idsrc="xmltag.org" >GERMANTOWN, Md.</location></span>, <span class="legendSpanClass"><chron>May 30, 2026</chron></span> /PRNewswire/ -- <span><a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4700195-1&amp;h=1290708377&amp;u=https%3A%2F%2Fprecigen.com%2F&amp;a=Precigen%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:PGEN" idsrc="xmltag.org" >Precigen, Inc.</span></a> (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of http://www.streetinsider.com/Press+Releases/Precigen+Presents+New+Long-Term+Durability+Data+for+PAPZIMEOS%2C+Recently+Granted+Seven-Year+Market+Exclusivity%2C+Demonstrating+Complete+Responses+Beyond+4+Years/26577264.html Sat, 30 May 2026 14:30:00 -0400 A.06822034 A.50216726 O.13607936 O.20026344 O.21612337 PGEN http://www.streetinsider.com/Press+Releases/Precigen+Presents+New+Long-Term+Durability+Data+for+PAPZIMEOS%2C+Recently+Granted+Seven-Year+Market+Exclusivity%2C+Demonstrating+Complete+Responses+Beyond+4+Years/26577264.html <div class="xn-content"> <ul type="disc"><li><i><span>15 out of 18 complete responders, or 83%, demonstrated ongoing complete responses for at least 36 months without any additional treatment for RRP</span></i></li><li><i><span>5 complete responders have ongoing responses beyond 4 years</span></i></li><li><i><span>Follow-up is ongoing; median duration of complete response has not yet been reached</span></i></li><li><i><span>No new adverse safety events have been observed during long-term follow-up</span></i></li><li><i><span><span value="ACORN:0682203466" idsrc="xmltag.org" >US FDA</span> granted seven-year period of orphan drug market exclusivity to PAPZIMEOS</span></i></li></ul><p><span class="legendSpanClass"><location value="LU/us.md.gerown" idsrc="xmltag.org" >GERMANTOWN, Md.</location></span>, <span class="legendSpanClass"><chron>May 30, 2026</chron></span> /PRNewswire/ -- <span><a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4700195-1&amp;h=1290708377&amp;u=https%3A%2F%2Fprecigen.com%2F&amp;a=Precigen%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:PGEN" idsrc="xmltag.org" >Precigen, Inc.</span></a> (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of http://www.streetinsider.com/Press+Releases/Precigen+Presents+New+Long-Term+Durability+Data+for+PAPZIMEOS%2C+Recently+Granted+Seven-Year+Market+Exclusivity%2C+Demonstrating+Complete+Responses+Beyond+4+Years/26577264.html Sat, 30 May 2026 14:30:00 -0400 A.06822034 A.50216726 O.13607936 O.20026344 O.21612337 PGEN http://www.streetinsider.com/Press+Releases/Precigen+Presents+New+Long-Term+Durability+Data+for+PAPZIMEOS%2C+Recently+Granted+Seven-Year+Market+Exclusivity%2C+Demonstrating+Complete+Responses+Beyond+4+Years/26577264.html <div class="xn-content"> <ul type="disc"><li><i><span>15 out of 18 complete responders, or 83%, demonstrated ongoing complete responses for at least 36 months without any additional treatment for RRP</span></i></li><li><i><span>5 complete responders have ongoing responses beyond 4 years</span></i></li><li><i><span>Follow-up is ongoing; median duration of complete response has not yet been reached</span></i></li><li><i><span>No new adverse safety events have been observed during long-term follow-up</span></i></li><li><i><span><span value="ACORN:0682203466" idsrc="xmltag.org" >US FDA</span> granted seven-year period of orphan drug market exclusivity to PAPZIMEOS</span></i></li></ul><p><span class="legendSpanClass"><location value="LU/us.md.gerown" idsrc="xmltag.org" >GERMANTOWN, Md.</location></span>, <span class="legendSpanClass"><chron>May 30, 2026</chron></span> /PRNewswire/ -- <span><a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4700195-1&amp;h=1290708377&amp;u=https%3A%2F%2Fprecigen.com%2F&amp;a=Precigen%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:PGEN" idsrc="xmltag.org" >Precigen, Inc.</span></a> (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of http://www.streetinsider.com/Press+Releases/Precigen+Presents+New+Long-Term+Durability+Data+for+PAPZIMEOS%2C+Recently+Granted+Seven-Year+Market+Exclusivity%2C+Demonstrating+Complete+Responses+Beyond+4+Years/26577264.html Sat, 30 May 2026 14:30:00 -0400 A.06822034 A.50216726 O.13607936 O.20026344 O.21612337 PGEN http://www.streetinsider.com/Press+Releases/Precigen+Presents+New+Long-Term+Durability+Data+for+PAPZIMEOS%2C+Recently+Granted+Seven-Year+Market+Exclusivity%2C+Demonstrating+Complete+Responses+Beyond+4+Years/26577264.html <div class="xn-content"> <ul type="disc"><li><i><span>15 out of 18 complete responders, or 83%, demonstrated ongoing complete responses for at least 36 months without any additional treatment for RRP</span></i></li><li><i><span>5 complete responders have ongoing responses beyond 4 years</span></i></li><li><i><span>Follow-up is ongoing; median duration of complete response has not yet been reached</span></i></li><li><i><span>No new adverse safety events have been observed during long-term follow-up</span></i></li><li><i><span><span value="ACORN:0682203466" idsrc="xmltag.org" >US FDA</span> granted seven-year period of orphan drug market exclusivity to PAPZIMEOS</span></i></li></ul><p><span class="legendSpanClass"><location value="LU/us.md.gerown" idsrc="xmltag.org" >GERMANTOWN, Md.</location></span>, <span class="legendSpanClass"><chron>May 30, 2026</chron></span> /PRNewswire/ -- <span><a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4700195-1&amp;h=1290708377&amp;u=https%3A%2F%2Fprecigen.com%2F&amp;a=Precigen%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:PGEN" idsrc="xmltag.org" >Precigen, Inc.</span></a> (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of http://www.streetinsider.com/Press+Releases/Precigen+Presents+New+Long-Term+Durability+Data+for+PAPZIMEOS%2C+Recently+Granted+Seven-Year+Market+Exclusivity%2C+Demonstrating+Complete+Responses+Beyond+4+Years/26577264.html Sat, 30 May 2026 14:30:00 -0400 A.06822034 A.50216726 O.13607936 O.20026344 O.21612337 PGEN http://www.streetinsider.com/Press+Releases/Precigen+Presents+New+Long-Term+Durability+Data+for+PAPZIMEOS%2C+Recently+Granted+Seven-Year+Market+Exclusivity%2C+Demonstrating+Complete+Responses+Beyond+4+Years/26577264.html <div class="xn-content"> <ul type="disc"><li><i><span>15 out of 18 complete responders, or 83%, demonstrated ongoing complete responses for at least 36 months without any additional treatment for RRP</span></i></li><li><i><span>5 complete responders have ongoing responses beyond 4 years</span></i></li><li><i><span>Follow-up is ongoing; median duration of complete response has not yet been reached</span></i></li><li><i><span>No new adverse safety events have been observed during long-term follow-up</span></i></li><li><i><span><span value="ACORN:0682203466" idsrc="xmltag.org" >US FDA</span> granted seven-year period of orphan drug market exclusivity to PAPZIMEOS</span></i></li></ul><p><span class="legendSpanClass"><location value="LU/us.md.gerown" idsrc="xmltag.org" >GERMANTOWN, Md.</location></span>, <span class="legendSpanClass"><chron>May 30, 2026</chron></span> /PRNewswire/ -- <span><a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4700195-1&amp;h=1290708377&amp;u=https%3A%2F%2Fprecigen.com%2F&amp;a=Precigen%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:PGEN" idsrc="xmltag.org" >Precigen, Inc.</span></a> (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of http://www.streetinsider.com/Press+Releases/Precigen+Presents+New+Long-Term+Durability+Data+for+PAPZIMEOS%2C+Recently+Granted+Seven-Year+Market+Exclusivity%2C+Demonstrating+Complete+Responses+Beyond+4+Years/26577264.html Sat, 30 May 2026 14:30:00 -0400 A.06822034 A.50216726 O.13607936 O.20026344 O.21612337 PGEN http://www.streetinsider.com/Press+Releases/Precigen+Presents+New+Long-Term+Durability+Data+for+PAPZIMEOS%2C+Recently+Granted+Seven-Year+Market+Exclusivity%2C+Demonstrating+Complete+Responses+Beyond+4+Years/26577264.html <div class="xn-content"> <ul type="disc"><li><i><span>15 out of 18 complete responders, or 83%, demonstrated ongoing complete responses for at least 36 months without any additional treatment for RRP</span></i></li><li><i><span>5 complete responders have ongoing responses beyond 4 years</span></i></li><li><i><span>Follow-up is ongoing; median duration of complete response has not yet been reached</span></i></li><li><i><span>No new adverse safety events have been observed during long-term follow-up</span></i></li><li><i><span><span value="ACORN:0682203466" idsrc="xmltag.org" >US FDA</span> granted seven-year period of orphan drug market exclusivity to PAPZIMEOS</span></i></li></ul><p><span class="legendSpanClass"><location value="LU/us.md.gerown" idsrc="xmltag.org" >GERMANTOWN, Md.</location></span>, <span class="legendSpanClass"><chron>May 30, 2026</chron></span> /PRNewswire/ -- <span><a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4700195-1&amp;h=1290708377&amp;u=https%3A%2F%2Fprecigen.com%2F&amp;a=Precigen%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:PGEN" idsrc="xmltag.org" >Precigen, Inc.</span></a> (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of http://www.streetinsider.com/Press+Releases/Precigen+Presents+New+Long-Term+Durability+Data+for+PAPZIMEOS%2C+Recently+Granted+Seven-Year+Market+Exclusivity%2C+Demonstrating+Complete+Responses+Beyond+4+Years/26577264.html Sat, 30 May 2026 14:30:00 -0400 A.06822034 A.50216726 O.13607936 O.20026344 O.21612337 PGEN http://www.streetinsider.com/PRNewswire/Precigen+Presents+New+Long-Term+Durability+Data+for+PAPZIMEOS%2C+Recently+Granted+Seven-Year+Market+Exclusivity%2C+Demonstrating+Complete+Responses+Beyond+4+Years/26577264.html <div class="xn-content"> <ul type="disc"><li><i><span>15 out of 18 complete responders, or 83%, demonstrated ongoing complete responses for at least 36 months without any additional treatment for RRP</span></i></li><li><i><span>5 complete responders have ongoing responses beyond 4 years</span></i></li><li><i><span>Follow-up is ongoing; median duration of complete response has not yet been reached</span></i></li><li><i><span>No new adverse safety events have been observed during long-term follow-up</span></i></li><li><i><span><span value="ACORN:0682203466" idsrc="xmltag.org" >US FDA</span> granted seven-year period of orphan drug market exclusivity to PAPZIMEOS</span></i></li></ul><p><span class="legendSpanClass"><location value="LU/us.md.gerown" idsrc="xmltag.org" >GERMANTOWN, Md.</location></span>, <span class="legendSpanClass"><chron>May 30, 2026</chron></span> /PRNewswire/ -- <span><a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4700195-1&amp;h=1290708377&amp;u=https%3A%2F%2Fprecigen.com%2F&amp;a=Precigen%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:PGEN" idsrc="xmltag.org" >Precigen, Inc.</span></a> (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of http://www.streetinsider.com/PRNewswire/Precigen+Presents+New+Long-Term+Durability+Data+for+PAPZIMEOS%2C+Recently+Granted+Seven-Year+Market+Exclusivity%2C+Demonstrating+Complete+Responses+Beyond+4+Years/26577264.html Sat, 30 May 2026 14:30:00 -0400 A.06822034 A.50216726 O.13607936 O.20026344 O.21612337 PGEN http://www.streetinsider.com/PRNewswire/Precigen+Presents+New+Long-Term+Durability+Data+for+PAPZIMEOS%2C+Recently+Granted+Seven-Year+Market+Exclusivity%2C+Demonstrating+Complete+Responses+Beyond+4+Years/26577264.html <div class="xn-content"> <ul type="disc"><li><i><span>15 out of 18 complete responders, or 83%, demonstrated ongoing complete responses for at least 36 months without any additional treatment for RRP</span></i></li><li><i><span>5 complete responders have ongoing responses beyond 4 years</span></i></li><li><i><span>Follow-up is ongoing; median duration of complete response has not yet been reached</span></i></li><li><i><span>No new adverse safety events have been observed during long-term follow-up</span></i></li><li><i><span><span value="ACORN:0682203466" idsrc="xmltag.org" >US FDA</span> granted seven-year period of orphan drug market exclusivity to PAPZIMEOS</span></i></li></ul><p><span class="legendSpanClass"><location value="LU/us.md.gerown" idsrc="xmltag.org" >GERMANTOWN, Md.</location></span>, <span class="legendSpanClass"><chron>May 30, 2026</chron></span> /PRNewswire/ -- <span><a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4700195-1&amp;h=1290708377&amp;u=https%3A%2F%2Fprecigen.com%2F&amp;a=Precigen%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:PGEN" idsrc="xmltag.org" >Precigen, Inc.</span></a> (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of http://www.streetinsider.com/PRNewswire/Precigen+Presents+New+Long-Term+Durability+Data+for+PAPZIMEOS%2C+Recently+Granted+Seven-Year+Market+Exclusivity%2C+Demonstrating+Complete+Responses+Beyond+4+Years/26577264.html Sat, 30 May 2026 14:30:00 -0400 A.06822034 A.50216726 O.13607936 O.20026344 O.21612337 PGEN http://www.streetinsider.com/PRNewswire/Precigen+Presents+New+Long-Term+Durability+Data+for+PAPZIMEOS%2C+Recently+Granted+Seven-Year+Market+Exclusivity%2C+Demonstrating+Complete+Responses+Beyond+4+Years/26577264.html <div class="xn-content"> <ul type="disc"><li><i><span>15 out of 18 complete responders, or 83%, demonstrated ongoing complete responses for at least 36 months without any additional treatment for RRP</span></i></li><li><i><span>5 complete responders have ongoing responses beyond 4 years</span></i></li><li><i><span>Follow-up is ongoing; median duration of complete response has not yet been reached</span></i></li><li><i><span>No new adverse safety events have been observed during long-term follow-up</span></i></li><li><i><span><span value="ACORN:0682203466" idsrc="xmltag.org" >US FDA</span> granted seven-year period of orphan drug market exclusivity to PAPZIMEOS</span></i></li></ul><p><span class="legendSpanClass"><location value="LU/us.md.gerown" idsrc="xmltag.org" >GERMANTOWN, Md.</location></span>, <span class="legendSpanClass"><chron>May 30, 2026</chron></span> /PRNewswire/ -- <span><a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4700195-1&amp;h=1290708377&amp;u=https%3A%2F%2Fprecigen.com%2F&amp;a=Precigen%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:PGEN" idsrc="xmltag.org" >Precigen, Inc.</span></a> (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of http://www.streetinsider.com/PRNewswire/Precigen+Presents+New+Long-Term+Durability+Data+for+PAPZIMEOS%2C+Recently+Granted+Seven-Year+Market+Exclusivity%2C+Demonstrating+Complete+Responses+Beyond+4+Years/26577264.html Sat, 30 May 2026 14:30:00 -0400 A.06822034 A.50216726 O.13607936 O.20026344 O.21612337 PGEN http://www.streetinsider.com/PRNewswire/Precigen+Presents+New+Long-Term+Durability+Data+for+PAPZIMEOS%2C+Recently+Granted+Seven-Year+Market+Exclusivity%2C+Demonstrating+Complete+Responses+Beyond+4+Years/26577264.html <div class="xn-content"> <ul type="disc"><li><i><span>15 out of 18 complete responders, or 83%, demonstrated ongoing complete responses for at least 36 months without any additional treatment for RRP</span></i></li><li><i><span>5 complete responders have ongoing responses beyond 4 years</span></i></li><li><i><span>Follow-up is ongoing; median duration of complete response has not yet been reached</span></i></li><li><i><span>No new adverse safety events have been observed during long-term follow-up</span></i></li><li><i><span><span value="ACORN:0682203466" idsrc="xmltag.org" >US FDA</span> granted seven-year period of orphan drug market exclusivity to PAPZIMEOS</span></i></li></ul><p><span class="legendSpanClass"><location value="LU/us.md.gerown" idsrc="xmltag.org" >GERMANTOWN, Md.</location></span>, <span class="legendSpanClass"><chron>May 30, 2026</chron></span> /PRNewswire/ -- <span><a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4700195-1&amp;h=1290708377&amp;u=https%3A%2F%2Fprecigen.com%2F&amp;a=Precigen%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:PGEN" idsrc="xmltag.org" >Precigen, Inc.</span></a> (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of http://www.streetinsider.com/PRNewswire/Precigen+Presents+New+Long-Term+Durability+Data+for+PAPZIMEOS%2C+Recently+Granted+Seven-Year+Market+Exclusivity%2C+Demonstrating+Complete+Responses+Beyond+4+Years/26577264.html Sat, 30 May 2026 14:30:00 -0400 A.06822034 A.50216726 O.13607936 O.20026344 O.21612337 PGEN http://www.streetinsider.com/PRNewswire/Precigen+Presents+New+Long-Term+Durability+Data+for+PAPZIMEOS%2C+Recently+Granted+Seven-Year+Market+Exclusivity%2C+Demonstrating+Complete+Responses+Beyond+4+Years/26577264.html <div class="xn-content"> <ul type="disc"><li><i><span>15 out of 18 complete responders, or 83%, demonstrated ongoing complete responses for at least 36 months without any additional treatment for RRP</span></i></li><li><i><span>5 complete responders have ongoing responses beyond 4 years</span></i></li><li><i><span>Follow-up is ongoing; median duration of complete response has not yet been reached</span></i></li><li><i><span>No new adverse safety events have been observed during long-term follow-up</span></i></li><li><i><span><span value="ACORN:0682203466" idsrc="xmltag.org" >US FDA</span> granted seven-year period of orphan drug market exclusivity to PAPZIMEOS</span></i></li></ul><p><span class="legendSpanClass"><location value="LU/us.md.gerown" idsrc="xmltag.org" >GERMANTOWN, Md.</location></span>, <span class="legendSpanClass"><chron>May 30, 2026</chron></span> /PRNewswire/ -- <span><a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4700195-1&amp;h=1290708377&amp;u=https%3A%2F%2Fprecigen.com%2F&amp;a=Precigen%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:PGEN" idsrc="xmltag.org" >Precigen, Inc.</span></a> (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of http://www.streetinsider.com/PRNewswire/Precigen+Presents+New+Long-Term+Durability+Data+for+PAPZIMEOS%2C+Recently+Granted+Seven-Year+Market+Exclusivity%2C+Demonstrating+Complete+Responses+Beyond+4+Years/26577264.html Sat, 30 May 2026 14:30:00 -0400 A.06822034 A.50216726 O.13607936 O.20026344 O.21612337 PGEN http://www.streetinsider.com/PRNewswire/Precigen+Presents+New+Long-Term+Durability+Data+for+PAPZIMEOS%2C+Recently+Granted+Seven-Year+Market+Exclusivity%2C+Demonstrating+Complete+Responses+Beyond+4+Years/26577264.html <div class="xn-content"> <ul type="disc"><li><i><span>15 out of 18 complete responders, or 83%, demonstrated ongoing complete responses for at least 36 months without any additional treatment for RRP</span></i></li><li><i><span>5 complete responders have ongoing responses beyond 4 years</span></i></li><li><i><span>Follow-up is ongoing; median duration of complete response has not yet been reached</span></i></li><li><i><span>No new adverse safety events have been observed during long-term follow-up</span></i></li><li><i><span><span value="ACORN:0682203466" idsrc="xmltag.org" >US FDA</span> granted seven-year period of orphan drug market exclusivity to PAPZIMEOS</span></i></li></ul><p><span class="legendSpanClass"><location value="LU/us.md.gerown" idsrc="xmltag.org" >GERMANTOWN, Md.</location></span>, <span class="legendSpanClass"><chron>May 30, 2026</chron></span> /PRNewswire/ -- <span><a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4700195-1&amp;h=1290708377&amp;u=https%3A%2F%2Fprecigen.com%2F&amp;a=Precigen%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:PGEN" idsrc="xmltag.org" >Precigen, Inc.</span></a> (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of http://www.streetinsider.com/PRNewswire/Precigen+Presents+New+Long-Term+Durability+Data+for+PAPZIMEOS%2C+Recently+Granted+Seven-Year+Market+Exclusivity%2C+Demonstrating+Complete+Responses+Beyond+4+Years/26577264.html Sat, 30 May 2026 14:30:00 -0400 A.06822034 A.50216726 O.13607936 O.20026344 O.21612337 PGEN http://www.streetinsider.com/Analyst+PT+Change/Precigen+Inc.+%28PGEN%29+PT+Raised+to+%2414+at+H.C.+Wainwright/26561037.html H.C. Wainwright analyst Swayampakula Ramakanth raised the price target on Precigen Inc. (NASDAQ: PGEN) to $14.00 (from $11.00) while maintaining a Buy rating. http://www.streetinsider.com/Analyst+PT+Change/Precigen+Inc.+%28PGEN%29+PT+Raised+to+%2414+at+H.C.+Wainwright/26561037.html Thu, 28 May 2026 07:07:44 -0400 PGEN http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PRECIGEN%2C+INC.++++++++++++For%3A+May+23++Filed+by%3A+Thomasian+Harry+Jr./26559691.html si-local-file:///var/storage/secattach/20260527/26559691.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PRECIGEN%2C+INC.++++++++++++For%3A+May+23++Filed+by%3A+Thomasian+Harry+Jr./26559691.html Wed, 27 May 2026 20:26:00 -0400 O.13607936 PGEN